IGFBP-3 sensitizes prostate cancer cells to interferon-gamma-induced apoptosis

Growth Hormone and IGF Research

Volumn 18, Issue 1, 2008, Pages 38-46

  Fang, Peng ^a   Hwa, Vivian ^a   Little, Brian M ^a   Rosenfeld, Ron G ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Apoptosis; IGFBP 3; Interferon gamma; mTOR; Prostate cancer; STAT1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GAMMA INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; STAT1 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTERFERON TYPE II; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION; TYROSINE;

EID: 39049111545     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.07.002     Document Type: Article

References (42)

1. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
2. Hwa V., Oh Y., and Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20 (1999) 761-787
3. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
4. Mohan S., and Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 175 (2002) 19-31
5. Oh Y., Muller H.L., Lee D.Y., Fielder P.J., and Rosenfeld R.G. Characterization of the affinities of insulin-like growth factor (IGF)- binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132 (1993) 1337-1344
6. Leal S.M., Liu Q., Huang S.S., and Huang J.S. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J. Biol. Chem. 272 (1997) 20572-20576
7. Ricort J.M., and Binoux M. Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J. Biol. Chem. 277 (2002) 19448-19454
8. Fanayan S., Firth S.M., and Baxter R.C. Signaling through the Smad pathway by insulin-like growth factor- binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J. Biol. Chem. 277 (2002) 7255-7261
9. Spagnoli A., Torello M., Nagalla S.R., et al. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J. Biol. Chem. 277 (2002) 18860-18867
10. Liu B., Lee H.Y., Weinzimer S.A., et al. Direct functional interactions between insulin-like growth factor- binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J. Biol. Chem. 275 (2000) 33607-33613
11. Gucev Z.S., Oh Y., Kelley K.M., and Rosenfeld R.G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 56 (1996) 1545-1550
12. Rozen F., Zhang J., and Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int. J. Oncol. 13 (1998) 865-869
13. Katz J., Nasatzky E., Werner H., Le Roith D., and Shemer J. Tumor necrosis factor alpha and interferon gamma-induced cell growth arrest is mediated via insulin-like growth factor binding protein-3. Growth Horm. IGF Res. 9 (1999) 174-178
14. Ikeda H., Old L.J., and Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13 (2002) 95-109
15. Fang P., Hwa V., and Rosenfeld R.G. Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp. Cell Res. 312 (2006) 1229-1239
16. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
17. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005) 375-386
18. Bae V.L., Jackson-Cook C.K., Maygarden S.J., Plymate S.R., Chen J., and Ware J.L. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate 34 (1998) 275-282
19. Buckway C.K., Wilson E.M., Ahlsen M., Bang P., Oh Y., and Rosenfeld R.G. Mutation of three critical amino acids of the N-terminal domain of IGF- binding protein-3 essential for high affinity IGF binding. J. Clin. Endocrinol. Metab. 86 (2001) 4943-4950
20. Hwa V., Little B., Kofoed E.M., and Rosenfeld R.G. Transcriptional regulation of insulin-like growth factor-I by interferon-gamma requires STAT-5b. J. Biol. Chem. 279 (2004) 2728-2736
21. Lee K.W., Liu B., Ma L., et al. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J. Biol. Chem. 279 (2004) 469-476
22. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence Jr. J.C., and Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. Embo J. 15 (1996) 5256-5267
23. Oh Y., Muller H.L., Lamson G., and Rosenfeld R.G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J. Biol. Chem. 268 (1993) 14964-14971
24. Pratt S.E., and Pollak M.N. Insulin-like growth factor binding protein-3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem. Biophys. Res. Commun. 198 (1994) 292-297
25. Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272 (1997) 12181-12188
26. Spagnoli A., Hwa V., Horton W.A., et al. Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. relationship to differentiation stage. J. Biol. Chem. 276 (2001) 5533-5540
27. Hong J., Zhang G., Dong F., and Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J. Biol. Chem. 277 (2002) 10489-10497
28. Lee H.Y., Chun K.H., Liu B., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res. 62 (2002) 3530-3537
29. Butt A.J., Fraley K.A., Firth S.M., and Baxter R.C. IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 143 (2002) 2693-2699
30. Kim H.S., Ingermann A.R., Tsubaki J., Twigg S.M., Walker G.E., and Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 64 (2004) 2229-2237
31. Silha J.V., Sheppard P.C., Mishra S., et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147 (2006) 2112-2121
32. Devi G.R., Sprenger C.C., Plymate S.R., and Rosenfeld R.G. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 51 (2002) 141-152
33. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., and Darnell Jr. J.E. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93 (1996) 7673-7678
34. Gill Z.P., Perks C.M., Newcomb P.V., and Holly J.M. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem. 272 (1997) 25602-25607
35. Williams A.C., Collard T.J., Perks C.M., et al. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 60 (2000) 22-27
36. Butt A.J., Firth S.M., King M.A., and Baxter R.C. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J. Biol. Chem. 275 (2000) 39174-39181
37. Fowler C.A., Perks C.M., Newcomb P.V., Savage P.B., Farndon J.R., and Holly J.M. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int. J. Cancer 88 (2000) 448-453
38. Fanayan S., Firth S.M., Butt A.J., and Baxter R.C. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF- beta) and the type II TGF-beta receptor. J. Biol. Chem. 275 (2000) 39146-39151
39. Collard T.J., Guy M., Butt A.J., et al. Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis 24 (2003) 393-401
40. Liu B., Lee K.W., Li H., et al. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res. 11 (2005) 4851-4856
41. Williams A.C., Smartt H., AM H.Z., Macfarlane M., Paraskeva C., and Collard T.J. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 14 (2007) 137-145
42. Jerome L., Alami N., Belanger S., et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 66 (2006) 7245-7252